Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Open Access
- 13 September 2022
- journal article
- research article
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 56 (5) , 249-259
Abstract
Background: Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR mutations via peptide nucleic acid clamping-assisted fluorescence melting curve analysis (PANAMutyper) and evaluated the feasibility of targeted deep sequencing for detecting the mutations.Methods: We examined EGFR mutations in exons 18 through 21 for 2,088 LUADs from July 2017 to April 2020 using PANAMutyper. Of these, we performed targeted deep sequencing in 73 patients and evaluated EGFR-mutation status and TKI clinical response.Results: EGFR mutation was identified in 55.7% of LUADs by PANAMutyper, with mutation rates higher in females (69.3%) and never smokers (67.1%) and highest in the age range of 50 to 59 years (64.9%). For the 73 patients evaluated using both methods, next-generation sequencing (NGS) identified EGFR mutation–positive results in 14 of 61 patients (23.0%) who were EGFR-negative according to PANAMutyper testing. Of the 10 patients reportedly harboring a sensitizing mutation according to NGS, seven received TKI treatment, with all showing partial response or stable disease. In the 12 PANAMutyper-positive cases, NGS identified two additional mutations in exon 18, whereas a discordant negative result was observed in two cases.Conclusions: Although PANAMutyper identified high frequencies of EGFR mutations, targeted deep sequencing revealed additional uncommon EGFR mutations. These findings suggested that appropriate use of NGS may benefit LUAD patients with otherwise negative screening test results.Keywords
Funding Information
- Ministry of Science and ICT
- National Research Foundation of Korea (2022R1A5A6000840)
- Korean Society of Pathologists (KSPG 2019-02)
This publication has 41 references indexed in Scilit:
- The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung CancerMedicine, 2015
- Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the LungJournal of Thoracic Oncology, 2015
- Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patientsThoracic Cancer, 2015
- EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic SurveyJournal of Thoracic Oncology, 2015
- Associations Between Mutations and Histologic Patterns of Mucin in Lung AdenocarcinomaAmerican Journal of Surgical Pathology, 2014
- The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomasCancer Cytopathology, 2012
- High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical FeaturesJournal of Thoracic Oncology, 2012
- Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma ClassificationArchives of Pathology & Laboratory Medicine, 2011
- Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the LungJournal of Thoracic Oncology, 2010